When did it all start?
An outbreak that began from Wuhan, China, has rapidly spread across various parts of the world.
31st December 2019, China reported cases of pneumonia associated with the Huanan Seafood Wholesale market in Wuhan, Hubei province.
On 7th January 2020, the Chinese health authorities confirmed the cases with a novel coronavirus outbreak.
The associated reports for increasing cases indicated that the transmission took place from person to person.
On 30th January 2020, 9,976 cases were reported in around 21 countries.
Since then, 2020 started with an outbreak of COVID-19 which WHO, in March, declared a “Pandemic”.
Countries are lurking with infected streets making them unfit and unsafe for anyone to walk around without getting attacked by the Covid-19 virus.
Scientists in various countries are busy experimenting and creating vaccines to get rid of the dawn that started in December 2019.
Various countries, India, China, Russia, and many others were trying to build a vaccine.
Russia, on 18th June, carried out the trials of two forms of potential COVID-19 vaccine, after successfully developing one.
It was developed by the Gamaleya National Research Centre of Epidemiology and Microbiology.
On July 15th and July 20th, the volunteers were freed from the trials proving that the vaccine was safe.
18 and 20 volunteers were involved in the first and second groups, respectively at Sechenov University.
Results of COVID-19 vaccines prove that the volunteers were building immunity towards coronavirus.
Why did India Deny The Vaccine Trials On Large Numbers?
After the trials were conducted on residents of Russia, they found the vaccine to be appropriate for the novel coronavirus pandemic to stop. They further distributed the vaccines to various countries including India.
The COVID-19 vaccine was called SPUTNIK-V.
India’s drug regulator has asked to conduct the test on a smaller trial rather than starting on a large number of people in the country.
In original trials, only Russian volunteers were involved.
No inputs were available on Indian participants and therefore the Central Drugs Standard Control Organisation has asked for a smaller version of the trial.
Russia was the first country to approve for the trial vaccines on such a large scale.
Various sections need to be studied if the trials will be held out on a large number of people.
Accidental damage and outbreak of other infections might be another outcome, if not successful on Indians.